The present invention concerns new pharmaceutical active ingredient combinations from new compounds of non-nucleoside reverse transcriptase inhibitors with one or more additional and different antivirally active pharmaceutical ingredient(s). Furthermore, the present invention concerns the combined use of said pharmaceutical active ingredient combinations for the prevention and/or treatment of viral infections and of diseases caused by them. The combination partners in accordance with the invention preferably belong to different antiretroviral drug action classes and can be administered simultaneously in a single pharmaceutical composition or are provided separately in different pharmaceutical dosage forms that can be administered either simultaneously or sequentially. In particular, selected combination partners can be provided in proportions with synergistic antiviral effect. In particular, the present inventions concerns the combined use of said pharmaceutical active ingredient combinations for prevention and/or treatment of retroviral infections as well as of diseases caused by retroviruses, such as HIV infections, and of diseases such as AIDS, caused by them in humans and/or animals.